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Inhibition of tissue-type plasminogen activator (t-PA) by pooled plasma could be ascribed for only 60% 
to the endothelial cell type PA inhibitor. The residual inhibition is ascribed to a so-far undescribed plasma 
component present at 0.2 nmol/l. This component shows reversible binding to t-PA with an apparent K, 
of 10 pmol/l (does not hinder t-PA binding to fibrin); also reacts with urokinase, but not with DIP-t-PA; 
is stable at 37°C and does not occur in media of endothelial cells, hepatocytes and fibroblasts. This PA 
binding component inplasma dds to the regulation of plasminogen activator activities. 
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1. INTRODUCTION 
t-PA and urokinase are specific proteases that 
activate fibrinolysis by converting the zymogen 
plasminogen into the fibrin degrading protease 
plasmin [ 11. The activity of plasminogen activators 
has recently been found to be controlled by a very 
potent PA inhibitor. This inhibitor has been found 
in plasma, platelets and in conditioned media of 
endothelial cells and hepatocytes [2,3]. Its activity 
can be assayed by titration with t-PA [4]. Other 
plasminogen activator inhibitors identified con- 
cern a placental inhibitor [5] and protease nexin 
161. 
The PA inhibitor has been purified from condi- 
tioned media of endothelial cells and an antiserum 
that neutralizes the activity of the inhibitor has 
recently been obtained [7]. 
With the use of the afore-mentioned antiserum 
and in the studies on the thermolability of the PA 
Abbreviations: t-PA, tissue type plasminogen activator; 
PA, plasminogen activator; IgG, immunoglobulin G; 
DDAVP, desamino-D-arginine vasopressin; DFP, 
diisopropyl phosphofluoridate 
inhibitor, we recently observed that in plasma a 
portion of t-PA inhibitory potential was not 
neutralized by the antiserum and that the same 
portion was thermostable. 
2. MATERIALS AND METHODS 
t-PA (spec. act. 5 x 10’ IU/mg) was purified 
from melanoma cell cultures. t-PA was inactivated 
by treatment with 1 mM DFP for 45 min and 
subsequent dialysis. Urokinase and bovine throm- 
bin were obtained from Leo, Ballerup, Denmark. 
IgGs from an antiserpm raised against PA in- 
hibitor from endothelial cell culture [7] were 
prepared on protein A-Sepharose (Pharmacia, 
Uppsala). 
Inhibitor purified from placenta and a neutraliz- 
ing antiserum were kindly provided by Dr N. 
Heimburger, Behringwerke, Marburg, FRG. 
Platelet-poor pooled normal plasma was obtained 
from 15-20 healthy volunteers. Plasma sampled 
30 min after the start of infusion of 0.4~g/kg of 
DDAVP was provided by Dr E.J.P. Brommer. 
Serum-free conditioned media of umbilical cord 
endothelial cells, hepatocytes and skin fibroblasts 
Published by Elsevier Science Publishers B. V. (Biomedicai Division) 
00145793/85/$3.30 0 1985 Federation of European Biochemical Societies 315 
Volume 190, number 2 FEBS LETTERS October 1985 
were provided by Drs T. Kooistra, H.M.G. 
Princen and A.L. van Wezel. Pooled plasma was 
freed of endothelial cell type PA inhibitbr by over- 
night incubation at 37°C or immunoprecipitation 
with the endothelial cell type PA inhibitor IgGs 
(60 min incubation of the mixture followed by 
15 min incubation with protein A-Sepharose and 
centrifugation). For coagulation of plasma, 600 ~1 
titrated plasma was mixed with t-PA or buffer 
(5 ~1) and clotted 10 min by addition of 50 ~1 
thrombin (20 NIH-U/ml) and 50 ,J of 0.05 M 
CaC12. 
3. RESULTS AND DISCUSSION 
3.1. Identification 
In a pooled normal plasma the titration assay of 
t-PA inhibition [4] yielded an inhibition level 
which, expressed in the amount of two-chain t-PA 
neutralized, amounts to 13 IU/ml or 0.45 nmol/l 
(fig. 1). 
The addition of an excess (lOrg/ml, lo-times 
above the &) of IgG against endothelial cell type 
PA inhibitor (or immunoprecipitation of plasma) 
only neutralizes the inhibition recorded in the 
pooled plasma to a residual level of 6 IU/ml. 
Similar inhibition levels in conditioned media of 
endothelial cells and hepatocytes were found to be 
neutralized completely by the excess of antibodies 
(not shown). 
Incubation of plasma or conditioned media of 
endothelial cells and hepatocytes at 37°C shows a 
gradual decline of t-PA inhibition with a half-life 
of 80-100 min [8,9]. In the cell media the residual 
activity after 24 h is negligible. In pooled plasma, 
however, even after incubation for a week, a 
residual activity amounting to 6 IU/ml remains. 
It was shown that the residual activity after in- 
cubation at 37°C was insensitive to the PA in- 
hibitor antibodies and the inhibitory activity re- 
maining, after immunoprecipitation of the plasma 
with the PA inhibitor antibodies, was stable at 
37°C. 
Apparently, plasma unlike cell conditioned 
media, contains a t-PA inhibitory component 
which differs immunochemically and in stability 
from the known endothelial cell type PA inhibitor. 
The inhibitory component was found not to be 
neutralized by antibodies directed towards the 
placenta inhibitor, while in other experiments these 
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Fig.1. Titration assay of t-PA inhibition in plasma 
samples. The ordinate records the acceleration constant 
in AA 40snrn/? (hM2); the abscissa records the amount of 
added t-PA expressed in NJ/ml of plasma. A linear 
dose-response curve for added t-PA is obtained in the 
buffer control. Curve 1, pooled normal plasma (20 pl in 
the assay volume of 250~1); curve 2, pooled plasma 
freed of PA inhibitor by overnight incubation at 37°C of 
the plasma. 
antibodies were found in the same assay to 
neutralize the inhibitory activity of the placenta in- 
hibitor towards t-PA. Other known plasmatic pro- 
tease inhibitors have much higher concentrations 
(several orders of magnitude) and are excluded 
from involvement (cf. [4]). The kinetic parameters 
of the inhibition are very different from those of 
protease nexin [6]. Additionally, we could not 
demonstrate with the titration assay any t-PA in- 
hibition in human skin fibroblast cultures further 
excluding the fact that protease nexin was 
involved. 
3.2. Kinetic analysis 
The inhibition curve for the thermostable com- 
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ponent (fig.1) shows a gradual bending suggesting 
an unfinished or reversible reaction. By extending 
the assay time up to 5 h in a situation similar to the 
indicated point I in fig.1 no change in residual t- 
PA activity was determined indicating that the 
reaction had reached an equilibrium. As shown in 
table 1, the greater the dilution of the mixture with 
a fixed ratio of t-PA and plasma, the larger the 
percentage of residual, free t-PA in accordance 
with the occurrence of a reversible equilibrium. 
Assuming a reversible 1: 1 complex formation of 
t-PA with the thermostable component, a double- 
reciprocal plot of free vs bound t-PA shows an ap- 
parent inhibition constant of 10 pmol/l and a con- 
centration of 0.2 nmol/l of the inhibitory 
component. 
3.3. Specificity 
The inhibition assay in pooled plasma only con- 
taining the thermostable component was similar 
for two-chain and one-chain t-PA. The addition of 
an excess (2 nmol/l plasma) of two-chain t-PA in- 
activated by treatment with DFP did not interfere 
with the recording in the assay. This indicates that 
the active site is involved in the interaction. 
Urokinase also interacts since addition of 
urokinase showed a gradual reduction in the in- 
hibition recorded with a 50% reduction with 
0.4 nmol/l plasma of added urokinase. 
3.4. Reversibility 
The reaction with t-PA was not only reversible 
in the assay system as demonstrated above but also 
in plasma. To pooled plasma with a total in- 
hibitory capacity of 13 III/ml we added buffer or 
Table 1 
Dilution of t-PA and PA inhibitor-free plasmaa 
Dilution % residual t-PA activityb 
1:l 22 
I:3 33 
1: 10 38 
a Constant ratio between t-PA and plasma 
b Measured at a point similar to point I in fig.1; below 
equivalence at 6 IU/ml 
15 or 30 IU/ml two-chain t-PA. In the two latter 
cases, upon direct analysis, the inhibitory capacity 
of the plasma was found to be neutralized com- 
pletely. After incubation at 37°C for 24 h we 
found in all 3 samples the same residual inhibitory 
capacity of about 6 IU/ml. The thermostable com- 
ponent had apparently been neutralized by the 
added t-PA only temporarily and obviously the t- 
PA had been inactivated during the incubation by 
other plasmatic inhibitors such as az-antiplasmin. 
Similar results were obtained with urokinase. The 
effects with endogenous t-PA were also similar. In 
samples of 2 volunteers given DDAVP, at 30 min 
after the start of infusion the inhibitory potential 
was found to be zero, due to neutralization by the 
release of endogenous t-PA. Upon incubation of 
these plasma samples for 24 h at 37°C the in- 
hibitory potential was found to return to a level 
similar to the thermostable portion in the plasma 
pre-infusion. 
We investigated, in plasma only containing the 
thermostable inhibitory component, whether the 
thermostable component inhibited the binding of 
t-PA to fibrin. Plasma was mixed with 3.5, 6 or 
12 IU/ml two-chain t-PA and clotted with a 
calcium/thrombin mixture (see section 2) and the 
clot removed. In the remaining serum, in all situa- 
tions, about 6 IU/ml of inhibition of t-PA was 
recorded, similar to the initial value and buffer 
control. This indicates that the added t-PA was 
bound completely to the clot. 
In conclusion, the putative new component is 
present in plasma in very low concentrations of 
about 0.2 nmol/l. The most striking characteristic 
of the component is the reversibility of the reaction 
with plasminogen activators as apparent from the 
kinetic analysis and from the incubations of 
plasma with t-PA and urokinase. Also the inhibi- 
tion of t-PA by the component does not involve 
the inhibition of its fibrin binding during clotting. 
It is proposed that the component presents a t-PA 
and urokinase binding component of plasma. 
It can be calculated from the kinetic data that at 
the very low plasmatic concentrations of t-PA and 
the component, the association is sufficient to give 
nearly complete binding of the t-PA to the PA 
binding component. It needs further study to find 
how this PA binding component regulates in con- 
cert with the PA inhibitor, the availability and ac- 
tions of plasminogen activators. 
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